Thrombolex, Inc., a commercial-stage developer of a differentiated pharmacomechanical lysis platform for the treatment of pulmona ...

Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...

Reinventing pulmonary care medically improves early diagnosis and interdisciplinary management for complex patients with COPD and co-morbidities.

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of ...

The first clinical practice guideline on acute pulmonary embolism (PE) from the American Heart Association and the American ...

Pulmonary involvement is highly prevalent in individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), affecting 82.7% of patients with granulomatosis with polyangiitis ...

Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 ...

Asthma and chronic obstructive pulmonary disease patients will receive better care closer to home under a landmark £10million partnership Care for ...

Hunt Regional Healthcare recently announced the purchase of Pulmonary Associates of Greenville, calling it an effort to secure a critical medical care specialty in the region for the future. Dr.

BioCardia ®, Inc. [NASDAQ: BCDA] , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its ...

A pulmonologist discusses the history and influence of race-based reference equations in pulmonary function testing interpretation and patient care.

CEO Barry Quart outlined the company’s focus on rademikibart, an IL-4 receptor alpha monoclonal antibody he described as a ...